• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $719 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-50 Mln

PureTech Health PLC (PRTC) Share Price

$26.73

As on 01-Mar-2024 10:27 EST

up-down-arrow $1.536.07%

  • Prev Close info

    $25.20

  • Day's Openinfo

    $25.92

  • Today's Highinfo

    $26.73

  • Today's Lowinfo

    $25.92

  • Today's Volumeinfo

    825

  • 52 Week rangeinfo

    $0.00 - 33.07

Please wait...

PureTech Health PLC (PRTC) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
PureTech Health PLC (PRTC)
-5.15 6.28 33.98 -7.80 -21.25 -- --
S&P BSE Sensex*
2.17 3.02 9.37 24.23 13.97 15.40 13.33
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 02-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
PureTech Health PLC (PRTC)
-11.66 -13.78 -31.48
S&P Small-Cap 600
13.89 -17.42 25.27
S&P BSE Sensex
18.74 4.44 21.99

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

PureTech Health PLC (PRTC) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of PureTech Health PLC (PRTC)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of PureTech Health PLC (PRTC)

        Founder, CEO & Executive Director

        Ms. Daphne Zohar

        President & Executive Director

        Dr. Bharatt M. Chowrira J.D., Ph.D.

        Headquarters

        Boston, MA

        FAQs for PureTech Health PLC (PRTC)

        The total asset value of PureTech Health PLC (PRTC) stood at $ 743 Mln as on 30-Jun-23

        The share price of PureTech Health PLC (PRTC) is $26.73 (NASDAQ) as of 01-Mar-2024 10:27 EST. PureTech Health PLC (PRTC) has given a return of -21.25% in the last 3 years.

        PureTech Health PLC (PRTC) has a market capitalisation of $ 719 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of PureTech Health PLC (PRTC) is 1.37 times as on 29-Feb-2024, a -0.54% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of PureTech Health PLC (PRTC) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the PureTech Health PLC (PRTC) and enter the required number of quantities and click on buy to purchase the shares of PureTech Health PLC (PRTC).

        PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. Address: 6 Tide Street, Boston, MA, United States, 02210

        The CEO & director of Ms. Daphne Zohar. is PureTech Health PLC (PRTC), and CFO & Sr. VP is Dr. Bharatt M. Chowrira J.D., Ph.D..

        The promoters of PureTech Health PLC (PRTC) have pledged 0% of the total equity as on Sep-23.

        PureTech Health PLC (PRTC) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of PureTech Health PLC (PRTC) was $-50 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $718.77 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-50.01 Mln
        • Cash date-information $352.14 Mln
        • Total Debt info $25.58 Mln
        • Insider's Holding 0.00%
        • Liquidity liquidity Low
        • 52 Week range week-range $0.00 - 33.07
        • Shares outstanding share-outstanding 26,995,000
        • 10 Years Aggregate:

          CFO: $-834.49 Mln

          EBITDA: $-1,062.13 Mln

          Net Profit: $179.02 Mln

        About The Company

        • IPO Date 16-Nov-2020
        • Founder, CEO & Executive Director Ms. Daphne Zohar
        • President & Executive Director Dr. Bharatt M. Chowrira J.D., Ph.D.
        • Listing key-listing NASDAQ: PRTC
        • Country United States
        • Headquarters headquarters Boston, MA
        • Website website https://www.puretechhealth.com
        • Business

          PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3...  stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. Address: 6 Tide Street, Boston, MA, United States, 02210  Read more

        share-fund-plan-icon